ABL Tyrosine Kinase Inhibitors Linked to Arterial Thrombosis – Blood Journals Portfolio
Blood Journals Portfolio shared a post on LinkedIn about a recent article by Richard Travers et al, published in Blood VTH:
”Another important study in observance of Deep Vein Thrombosis Awareness Month, focusing on Arterial Thrombosis.
‘Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis’ published on January 7, 2026, concluded that Dasatinib, ponatinib, and nilotinib damage ECs in different ways, all of which can contribute to arterial thrombosis.”
Title: Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis
Authors: Richard Travers, Alec Stepanian, Sebastiana Redford, Gregory Martin, Nicole L. Svedberg, Kun Xu, Glenn Merrill-Skoloff, Christopher Chen, Robert Flaumenhaft, Iris Z. Jaffe
Read the Full Article on Blood VTH
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 24, 2026, 16:21Wolfgang Miesbach: Infections as a Trigger for Stroke in Young Adults
-
Mar 24, 2026, 16:19Sue Hill: How a Biomedical Scientist’s Curiosity is Improving Patient Care
-
Mar 24, 2026, 16:16Seema Dawood: Platelet Satellitism – An EDTA-Dependent Cause of Pseudothrombocytopenia
-
Mar 24, 2026, 16:16New WECARE Study Highlights the Real-World Challenges of Living with Hemophilia – WFH
-
Mar 24, 2026, 16:13Omar Alami: What Mentorship Within The Bleeding Disorder Community Meant to Me
-
Mar 24, 2026, 16:11Tiago Pina Cabral: Can Port Maintenance be Safely Extended to 24 Weeks After Treatment Completion?
-
Mar 24, 2026, 16:09Rob Mac Sweeney: Current Perspectives and Updated Transfusion Strategies in Critically Ill Anemic Patients
-
Mar 24, 2026, 16:08Nathan Connell: The Boston Bleeding Disorders Center Announces Its $150,000 Research Award Application
-
Mar 24, 2026, 16:07Suvro Sankha Datta: IVIG-Induced Hemolysis and the Role of ABO Antibodies